{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:30:35Z","timestamp":1773113435019,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cisplatin-based chemoradiotherapy (CRT) is standard treatment for head and neck squamous cell carcinoma (HNSCC). However, IMRT may increase chemotherapy-induced nausea and vomiting (CINV). The purpose of this study is to investigate the effect of fosaprepitant in preventing CINV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An infusion of 150\u00a0mg fosaprepitant was given through a 30 min. We assessed acute toxicity using CTCAE v.4 and the incidence of CINV using the FLIE questionnaire. The evaluation of CINV was done at the second and fifth weeks of CRT and 1\u00a0week after the end. The EORTC QLQ-HN 43 questionnaire was administered before treatment beginning (baseline), at second (T1) and fifth (T2) weeks. A dosimetric analysis was performed on dorsal nucleus of vagus (DVC) and area postrema (AP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between March and November 2020, 24 patients were enrolled. No correlation was found between nausea and DVC mean dose (<jats:italic>p<\/jats:italic>\u2009=\u20090.573), and AP mean dose (<jats:italic>p<\/jats:italic>\u2009=\u20090.869). Based on the FLIE questionnaire, patients reported a mean score of 30.5 for nausea and 30 for vomiting during week 2 and 29.8 for nausea and 29.2 for vomiting during week 5. After treatment ended, the mean scores were 27.4 for nausea and 27.7 for vomiting. All patients completed the EORTC QLQ-HN 43. Significantly higher scores at T2 assessment than baseline were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The use of fosaprepitant in preventing CINV reduced incidence of moderate to severe nausea and vomiting. No correlation has been found between nausea and median dose to DVC and AP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11547-024-01757-3","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T02:02:34Z","timestamp":1707876154000},"page":"457-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature"],"prefix":"10.1007","volume":"129","author":[{"given":"Carlotta","family":"Becherini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9793-500X","authenticated-orcid":false,"given":"Viola","family":"Salvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Vagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Visani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vieri","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"crossref","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 92(1):4\u201314","DOI":"10.1016\/j.radonc.2009.04.014"},{"issue":"21","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","volume":"26","author":"M Machtay","year":"2008","unstructured":"Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582\u20133589","journal-title":"J Clin Oncol"},{"key":"1757_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctrv.2017.07.003","volume":"59","author":"P Strojan","year":"2017","unstructured":"Strojan P, Hutcheson KA, Eisbruch A et al (2017) Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev. 59:79\u201392","journal-title":"Cancer Treat Rev."},{"issue":"26","key":"1757_CR4","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1200\/JCO.2007.13.3983","volume":"25","author":"SM Bentzen","year":"2007","unstructured":"Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 25(26):4096\u20134103","journal-title":"J Clin Oncol."},{"issue":"23","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"1","key":"1757_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109","journal-title":"J Clin Oncol"},{"issue":"722","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2013.09.071","volume":"5","author":"C Kamen","year":"2014","unstructured":"Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 5(722):172\u2013179","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1757_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00520-008-0445-x","volume":"17","author":"A Enblom","year":"2008","unstructured":"Enblom A, Bergius Axelsson B, Steineck G, Hammar M, B\u00f6rjeson S (2008) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17(1):23\u201332","journal-title":"Support Care Cancer"},{"issue":"3","key":"1757_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00520-012-1574-9","volume":"21","author":"C Pirri","year":"2013","unstructured":"Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, Bennett R (2013) Nausea still the poor relation in antiemetic therapy? The impact on cancer patients\u2019 Quality of Life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer 21(3):735\u2013748","journal-title":"Support Care Cancer"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11547-016-0722-6","volume":"122","author":"L Lastrucci","year":"2017","unstructured":"Lastrucci L, Bertocci S, Bini V et al (2017) Late toxicity, evolving radiotherapy techniques, and Quality of Life in nasopharyngeal carcinoma. Radiol med 122:303\u2013308","journal-title":"Radiol med"},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related Quality of Life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13\u201336","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1757_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00520-018-4586-2","volume":"27","author":"E McKenzie","year":"2019","unstructured":"McKenzie E, Zaki P, Raman S et al (2019) Radiation-induced nausea and vomiting: a comparison between MASCC\/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 27(3):783\u2013791. https:\/\/doi.org\/10.1007\/s00520-018-4586-2","journal-title":"Support Care Cancer"},{"issue":"1","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"11","key":"1757_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1586\/14737140.8.11.1733","volume":"8","author":"RM Navari","year":"2008","unstructured":"Navari RM (2008) Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 8(11):1733\u20131742. https:\/\/doi.org\/10.1586\/14737140.8.11.1733","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"1757_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","volume":"26","author":"R Clark-Snow","year":"2018","unstructured":"Clark-Snow R, Affronti ML, Rittenberg CN (2018) Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 26(2):557\u2013564. https:\/\/doi.org\/10.1007\/s00520-017-3866-6","journal-title":"Support Care Cancer"},{"issue":"3","key":"1757_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0895-4356(02)00585-1","volume":"56","author":"V de Groot","year":"2003","unstructured":"de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 56(3):221\u2013229. https:\/\/doi.org\/10.1016\/s0895-4356(02)00585-1","journal-title":"J Clin Epidemiol."},{"issue":"10","key":"1757_CR17","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/s0959-8049(03)00299-5","volume":"39","author":"AR Martin","year":"2003","unstructured":"Martin AR, Carides AD, Pearson JD et al (2003) Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer. 39(10):1395\u20131401. https:\/\/doi.org\/10.1016\/s0959-8049(03)00299-5","journal-title":"Eur J Cancer."},{"key":"1757_CR18","doi-asserted-by":"crossref","unstructured":"Singer S, Ara\u00fajo C, Arraras JI et al. on behalf of the EORTC Quality of Life and the EORTC head and neck cancer groups (2015) Measuring Quality of Life in patients with head and neck cancer: update of the EORTC QLQ-H&N module, phase III. Head neck. 37, 1358\u20131367","DOI":"10.1002\/hed.23762"},{"key":"1757_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.radonc.2018.08.003","volume":"130","author":"A Beddok","year":"2019","unstructured":"Beddok A, Faivre JC, Coutte A et al (2019) Practical contouring guidelines with an MR-based atlas of brainstem structures involved in radiation-induced nausea and vomiting. Radiother Oncol 130:113\u2013120","journal-title":"Radiother Oncol"},{"issue":"suppl 5","key":"1757_CR20","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J et al (2016) MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133","journal-title":"Ann Oncol"},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"1757_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00520-013-1999-9","volume":"22","author":"L Schwartzberg","year":"2014","unstructured":"Schwartzberg L, Barbour SY, Morrow GR et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469\u2013477","journal-title":"Support Care Cancer"},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00520-014-2339-4","volume":"23","author":"T Kitazaki","year":"2015","unstructured":"Kitazaki T, Fukuda Y, Fukahori S et al (2015) Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy. Support Care Cancer 23:185\u2013190","journal-title":"Support Care Cancer"},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K et al (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859\u2013865","journal-title":"Br J Cancer"},{"issue":"5","key":"1757_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ijrobp.2015.04.037","volume":"92","author":"F Jahn","year":"2015","unstructured":"Jahn F, Riesner A, Jahn P, Sieker F, Vordermark D, Jordan K (2015) Addition of the neurokinin-1-receptor antagonist (RA) aprepitant to a 5-hydroxytryptamine-ra and dexamethasone in the prophylaxis of nausea and vomiting due to radiation therapy with concomitant cisplatin. Int J Radiat Oncol Biol Phys 92(5):1101\u20131107. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1757_CR26","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1007\/s00520-016-3306-z","volume":"24","author":"S Hanawa","year":"2016","unstructured":"Hanawa S, Mitsuhashi A, Matsuoka A et al (2016) Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study. Support Care Cancer 24(11):4633\u20134638. https:\/\/doi.org\/10.1007\/s00520-016-3306-z","journal-title":"Support Care Cancer"},{"issue":"4","key":"1757_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14(4):141\u2013147. https:\/\/doi.org\/10.12788\/jcso.0245","journal-title":"J Community Support Oncol"},{"issue":"4","key":"1757_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1470-2045(15)00615-4","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann CH, Christensen TB, Dohn LH et al (2016) Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 17(4):509\u2013518. https:\/\/doi.org\/10.1016\/s1470-2045(15)00615-4","journal-title":"Lancet Oncol"},{"issue":"5","key":"1757_CR29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00520-016-3540-4","volume":"25","author":"S Ades","year":"2017","unstructured":"Ades S, Halyard M, Wilson K et al (2017) Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). Support Care Cancer 25(5):1503\u20131510. https:\/\/doi.org\/10.1007\/s00520-016-3540-4","journal-title":"Support Care Cancer"},{"key":"1757_CR30","doi-asserted-by":"publisher","unstructured":"Wang Z, Liu W, Zhang J et al. (2021) Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting (C-RINV) in locally advanced head and heck squamous cell carcinoma: a prospective phase II trial, 01, PREPRINT (version 1) available at research square [https:\/\/doi.org\/10.21203\/rs.3.rs-948378\/v1]","DOI":"10.21203\/rs.3.rs-948378\/v1"},{"issue":"15","key":"1757_CR31","doi-asserted-by":"publisher","first-page":"e24122","DOI":"10.1200\/JCO.2020.38.15_suppl.e24122","volume":"38","author":"H D\u2019souza","year":"2020","unstructured":"D\u2019souza H, Noronha V, Patil VM et al (2020) Aprepitant in weekly cisplatin with radiation in head and neck cancer: is it required? J Clinical Oncology 38(15):e24122\u2013e24122","journal-title":"J Clinical Oncology"},{"issue":"Suppl 1","key":"1757_CR32","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.21037\/apm.2017.03.05","volume":"6","author":"J Stinson","year":"2017","unstructured":"Stinson J, Chan K, Lee J et al (2017) Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation. Ann Palliat Med 6(Suppl 1):S13\u2013S20. https:\/\/doi.org\/10.21037\/apm.2017.03.05","journal-title":"Ann Palliat Med"},{"issue":"suppl 1","key":"1757_CR33","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s00520-010-0950-6","volume":"19","author":"PC Feyer","year":"2011","unstructured":"Feyer PC, Maranzano E, Molassiotis A et al (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC\/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19(suppl 1):S5-14","journal-title":"Support Care Cancer"},{"key":"1757_CR34","unstructured":"Ettinger DS, Berger MJ, Ashton J et al. (2017) NCCN guidelines version 2.2017 Panel members antiemesis"},{"issue":"1","key":"1757_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/hed.25982","volume":"42","author":"F Paiar","year":"2020","unstructured":"Paiar F, Cristaudo A, Gonnelli A et al (2020) Radiation-induced nausea and vomiting in head and neck cancer: is it something worth considering in the intensity modulated radiotherapy era? \u201cA narrative review.\u201d Head Neck 42(1):131\u2013137","journal-title":"Head Neck"},{"issue":"3 Suppl","key":"1757_CR36","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.ijrobp.2009.08.078","volume":"76","author":"C Mayo","year":"2010","unstructured":"Mayo C, Yorke E, Merchant TE (2010) Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S36\u2013S41","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1757_CR37","first-page":"188","volume":"1","author":"F Busato","year":"2023","unstructured":"Busato F, Fiorentin D, Bettinelli A et al (2023) Dosiomic-based prediction of dysgeusia in head & neck cancer patients treated with radiotherapy. Radiother Oncol 1:188","journal-title":"Radiother Oncol"},{"issue":"5","key":"1757_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12032-019-1269-x","volume":"36","author":"S Martini","year":"2019","unstructured":"Martini S, Iorio GC, Arcadipane F et al (2019) Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer. Med Oncol 36(5):44","journal-title":"Med Oncol"},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11547-023-01707-5","volume":"128","author":"I Morelli","year":"2023","unstructured":"Morelli I, Desideri I, Romei A et al (2023) Impact of radiation dose on patient-reported acute taste alteration in a prospective observational study cohort in head and neck squamous cell cancer (HNSCC). La Radiol med 128:1\u20139","journal-title":"La Radiol med"},{"key":"1757_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2014.02.019","volume":"111","author":"E Kocak-Uzel","year":"2014","unstructured":"Kocak-Uzel E, Gunn GB, Colen RR et al (2014) Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol 111:281\u2013288","journal-title":"Radiother Oncol"},{"issue":"11","key":"1757_CR41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","volume":"36","author":"V Noronha","year":"2018","unstructured":"Noronha V, Joshi A, Patil VM et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 36(11):1064\u20131072. https:\/\/doi.org\/10.1200\/JCO.2017.74.9457","journal-title":"J Clin Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01757-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:23:49Z","timestamp":1710505429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01757-3","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}